Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04016805
Title Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib or Venetoclax
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
TG Therapeutics Investigational Trial Site Boston Massachusetts 02114 United States Details
TG Therapeutics Investigational Trial Site Hackensack New Jersey 07601 United States Details
TG Therapeutics Investigational Trial Site New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field